Developing and Treating a Mouse Model of Acute Myeloid Leukemia Using Tissue Samples From Younger Patients With Acute Myeloid Leukemia
RATIONALE: Studying tissue samples from patients with cancer in the laboratory may help doctors learn more about cancer and how well patients will respond to treatment.
PURPOSE: These laboratory trial studies the development and treatment of a mouse model for acute myeloid leukemia (AML) using samples from younger patients with AML.
|Official Title:||Development of Pediatric Acute Myeloid Leukemia Xenograft Models for the Testing of Targeted Therapeutic Agents|
- Ratio of human AML cells to murine cells [ Designated as safety issue: No ]
- Efficacy of sorafenib or quizartinib to inhibit AML proliferation in vivo [ Designated as safety issue: No ]
|Study Start Date:||April 2012|
|Estimated Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
- To determine the rate of engraftment of pediatric FMS-Like Tyrosine Kinase-3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) samples in NOD scid gamma (NSG) mice.
- To determine the efficacy of treatment of FLT3-ITD xenografts with tyrosine kinase inhibitors.
OUTLINE: Human acute myeloid leukemia cells are injected into NSG mice. Mice are then treated with sorafenib or quizartinib via gavage once daily for 28 days. Peripheral blood and tissue samples are collected biweekly or weekly and analyzed for the presence of human CD45+ and CD33+ cells by quantitative flow cytometry.
|Principal Investigator:||Sarah K. Tasian, MD||Children's Hospital of Philadelphia|